2021-2022 AMMI Canada guidance on the use of antiviral drugs for influenza in the COVID-19 pandemic setting in Canada.

J Assoc Med Microbiol Infect Dis Can

Division of Infectious Diseases, Department of Medicine, Kingston Health Sciences Centre, Queen's University, Kingston, Ontario, Canada.

Published: March 2022

We provide an update to the Association of Medical Microbiology and Infectious Disease Canada seasonal influenza foundation guideline on the use of antiviral drugs for influenza for the upcoming 2021-2022 influenza season in Canada. Peramivir and baloxavir marboxil were licensed in Canada in 2017 and 2020, respectively, but neither is currently marketed. Thus, this guidance continues to focus on further optimizing the use of oseltamivir and zanamivir. Important issues for this year include the implications of co-circulation of severe acute respiratory syndrome coronavirus 2 and influenza viruses; the role of diagnostic testing in relation to impact on patient management; and dosing and administration recommendations for neuraminidase inhibitors for various at-risk age groups.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9603021PMC
http://dx.doi.org/10.3138/jammi-2022-01-31DOI Listing

Publication Analysis

Top Keywords

antiviral drugs
8
drugs influenza
8
canada
5
influenza
5
2021-2022 ammi
4
ammi canada
4
canada guidance
4
guidance antiviral
4
influenza covid-19
4
covid-19 pandemic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!